08.26.21
Tageos launched its EOS-202 U9 RAIN RFID inlay. With the smallest form factor available today for healthcare and pharmaceutical applications, the new inlay has successfully passed latest tests specified by the Auburn University RFID Lab Spec S. Furthermore, EOS-202 U9 is certified by DoseID as suitable for a broad range of pharmaceutical and healthcare purposes.
The COVID-19 pandemic has highlighted the need for high-performance, resilient healthcare solutions worldwide. RFID technology contributes strongly to that by providing products for seamlessly tracking and tracing pharmaceutical items on a unit-of-use basis. DoseID, an industry consortium for the use of RFID technology in the healthcare and pharmaceutical space certifies RFID inlays for tracking of pharmaceuticals.
With the EOS-202 U9, Tageos is not simply expanding the range of DoseID certified and ARC Spec S approved inlays designed for unit-of-use medications and specimens in pharmaceutical applications. The French-headquartered RFID supplier is upgrading that range with a product of unique capabilities.
The new UHF product features a sophisticated, very-small-footprint antenna design measuring just 20x10 mm (wet inlay finished size 22x12 mm) alongside NXP’s UCODE9 IC. The IC complies with the EPC Class 1 Gen 2 protocol and the ISO 18000-6c standard for global use, and features auto-adjust technology, unique brand identifiers, and pre-serialized 96- bit EPC memory.
The chip and the antenna design tailored to it make EOS-202 U9 the market’s smallest RAIN RFID inlay (as of August 2021) to exhibit strong performance across all types of items currently tested according to ARC Spec S for healthcare and pharmaceutical applications.
Its read sensitivity and reliability, even in dense RFID tag populations, make the EOS-202 U9 viable for use across the latest portfolio of tested items outlined by ARC Spec S, including clear and amber liquid glass vials, clear glass powder vials, plastic/COC syringes, plastic syringe caps and plastic blow-fill-seal vials. That performance edge pays off in a wide range of hospital, pharmaceutical and inventory management workflows.
“The new EOS-202 U9 inlay underpins our strong commitment to always provide our customers with the most advanced products in terms of maximum performance, quality and sustainability. With its unique combination of the smallest size and optimum read characteristics in challenging environments, the new inlay provides the healthcare and pharmaceutical sector with the ultimate ‘one-size-fits-all’ solution,” said Chris Reese, head of product management at Tageos.
The COVID-19 pandemic has highlighted the need for high-performance, resilient healthcare solutions worldwide. RFID technology contributes strongly to that by providing products for seamlessly tracking and tracing pharmaceutical items on a unit-of-use basis. DoseID, an industry consortium for the use of RFID technology in the healthcare and pharmaceutical space certifies RFID inlays for tracking of pharmaceuticals.
With the EOS-202 U9, Tageos is not simply expanding the range of DoseID certified and ARC Spec S approved inlays designed for unit-of-use medications and specimens in pharmaceutical applications. The French-headquartered RFID supplier is upgrading that range with a product of unique capabilities.
The new UHF product features a sophisticated, very-small-footprint antenna design measuring just 20x10 mm (wet inlay finished size 22x12 mm) alongside NXP’s UCODE9 IC. The IC complies with the EPC Class 1 Gen 2 protocol and the ISO 18000-6c standard for global use, and features auto-adjust technology, unique brand identifiers, and pre-serialized 96- bit EPC memory.
The chip and the antenna design tailored to it make EOS-202 U9 the market’s smallest RAIN RFID inlay (as of August 2021) to exhibit strong performance across all types of items currently tested according to ARC Spec S for healthcare and pharmaceutical applications.
Its read sensitivity and reliability, even in dense RFID tag populations, make the EOS-202 U9 viable for use across the latest portfolio of tested items outlined by ARC Spec S, including clear and amber liquid glass vials, clear glass powder vials, plastic/COC syringes, plastic syringe caps and plastic blow-fill-seal vials. That performance edge pays off in a wide range of hospital, pharmaceutical and inventory management workflows.
“The new EOS-202 U9 inlay underpins our strong commitment to always provide our customers with the most advanced products in terms of maximum performance, quality and sustainability. With its unique combination of the smallest size and optimum read characteristics in challenging environments, the new inlay provides the healthcare and pharmaceutical sector with the ultimate ‘one-size-fits-all’ solution,” said Chris Reese, head of product management at Tageos.
